United Therapeutics (NASDAQ:UTHR) EVP Sells $4,467,870.00 in Stock

Key Points

• United Therapeutics EVP Paul Mahon sold 11,000 shares at an average price of $406.17, totaling nearly $4.47 million, resulting in a 23.02% decrease in his ownership stake.
• The company reported earnings of $6.41 per share for the last quarter, missing estimates by $0.39, despite a revenue increase of 11.7% year-over-year.
• Analysts have mixed ratings on UTHR, with price targets ranging from $328 to $560 and a consensus rating of "Moderate Buy".

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, September 18th. The stock was sold at an average price of $406.17, for a total transaction of $4,467,870.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $14,939,338.77. The trade was a 23.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Down 0.7%

Shares of United Therapeutics stock traded down $2.84 during trading hours on Monday, reaching $414.73. 695,995 shares of the company's stock were exchanged, compared to its average volume of 951,732. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The company has a market capitalization of $18.71 billion, a P/E ratio of 16.30, a price-to-earnings-growth ratio of 6.37 and a beta of 0.62. The business has a fifty day moving average of $329.55 and a two-hundred day moving average of $310.69.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same period in the previous year, the company earned $5.85 EPS. United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Jefferies Financial Group upped their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a report on Wednesday, September 10th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a report on Thursday, September 4th. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $438.85.

Institutional Trading of United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new stake in shares of United Therapeutics during the first quarter worth about $32,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.